We are live on ! Find out more
RYTM icon

Rhythm Pharmaceuticals
RYTM

279 hedge funds and large institutions have $7.8B invested in Rhythm Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 57 funds opening new positions, 106 increasing their positions, 89 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more first-time investments, than exits

New positions opened: 57 | Existing positions closed: 40

41% more call options, than puts

Call options by funds: $45.9M | Put options by funds: $32.5M

19% more repeat investments, than reductions

Existing positions increased: 106 | Existing positions reduced: 89

8% more capital invested

Capital invested by funds: $7.2B → $7.8B (+$598M)

6% more funds holding

Funds holding: 264 → 279 (+15)

2.45% more ownership

Funds ownership: 106.73% → 109.17% (+2.4%)

0% more funds holding in top 10

Funds holding in top 10: 10 → 10 (0)

Holders
279
Holders Change
+15
Holders Change %
+5.68%
% of All Funds
3.39%
Holding in Top 10
10
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.12%
New
57
Increased
106
Reduced
89
Closed
40
Calls
$45.9M
Puts
$32.5M
Net Calls
+$13.5M
Net Calls Change
-$21.7M

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$129M
2
RCM
RA Capital Management
Massachusetts
+$105M
3
Jennison Associates
Jennison Associates
New York
+$53.8M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$45.6M
5
Capital Research Global Investors
Capital Research Global Investors
California
+$41M

Top Sellers

1
Alkeon Capital Management
Alkeon Capital Management
New York
-$103M
2
Primecap Management
Primecap Management
California
-$83.2M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$46.6M
4
Voloridge Investment Management
Voloridge Investment Management
Florida
-$32.6M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$29.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
CIBC Asset Management
201
CIBC Asset Management
Ontario, Canada
$305K +$302K +2,848 New
Carson Wealth (CWM LLC)
202
Carson Wealth (CWM LLC)
Nebraska
$296K -$13.3K -125 -4%
SLAM
203
Swiss Life Asset Management
$284K +$20.4K +192 +8%
CPIG
204
Chicago Partners Investment Group
Illinois
$282K +$30.1K +284 +12%
ET
205
Entropy Technologies
New York
$267K -$638K -6,010 -71%
SOW
206
State of Wyoming
Wyoming
$261K +$158K +1,487 +156%
BNP Paribas Asset Management
207
BNP Paribas Asset Management
France
$259K +$203K +1,918 +386%
CF
208
Centaurus Financial
California
$256K – – –
VPIM
209
Vanguard Personalized Indexing Management
California
$255K +$33K +311 +15%
AHL
210
Abel Hall LLC
Louisiana
$229K +$227K +2,140 New
M&T Bank
211
M&T Bank
New York
$225K +$223K +2,101 New
CIM
212
Cambria Investment Management
California
$214K +$212K +1,997 New
EWP
213
Elevation Wealth Partners
California
$211K – – –
Jane Street
214
Jane Street
New York
$210K -$107K -1,008 -34%
KBC Group
215
KBC Group
Belgium
$183K – – –
WT
216
Whittier Trust
California
$180K – – –
Royal Bank of Canada
217
Royal Bank of Canada
Ontario, Canada
$180K -$13.2M -124,110 -99%
AB
218
Amalgamated Bank
New York
$178K -$3.18K -30 -2%
A
219
AlphaQuest
New York
$161K +$12.4K +117 +8%
PAP
220
Persistent Asset Partners
Hong Kong
$155K +$153K +1,446 New
GFM
221
GF Fund Management
China
$140K -$12.6K -119 -8%
CA
222
Clearstead Advisors
Ohio
$133K +$89.8K +847 +212%
DB
223
Danske Bank
Denmark
$118K +$117K +1,100 New
Osaic Holdings
224
Osaic Holdings
Arizona
$111K +$6.26K +59 +6%
US Bancorp
225
US Bancorp
Minnesota
$102K +$85.6K +807 +553%
7 8
9
10 11

RYTM Hedge Fund Activity: Q4 2025 in Review

279 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q4 2025, worth a combined $7.8B — up 8.3% from $7.2B a quarter earlier.

Buyers outnumbered sellers: 57 funds opened new RYTM positions and 40 closed out — a net gain of 17 holders — while 106 added to existing stakes and 89 trimmed.

The largest buyer was Vanguard Group, adding an estimated $129M. The largest seller was Alkeon Capital Management, exiting entirely with an estimated $103M sold.

  • 279 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q4 2025, up from 264 in Q3 2025.
  • Funds reported $7.8B of Rhythm Pharmaceuticals stock for Q4 2025, up 8.3% quarter-over-quarter.
  • 57 funds opened new Rhythm Pharmaceuticals positions in Q4 2025 and 40 closed out, a net change of +17 holders.
  • The largest Rhythm Pharmaceuticals buyer in Q4 2025 was Vanguard Group, an estimated $129M added.
  • The largest Rhythm Pharmaceuticals seller in Q4 2025 was Alkeon Capital Management, an estimated $103M sold.

Based on aggregated 13F filings for Q4 2025.